EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, MNKD: Mannkind Corp

12 Jun 26 15:59
LAST:

3.660

CHANGE:
 0.09		OPEN:
3.750		HIGH:
3.805		ASK:
3.600		VOLUME:
3.29M
CHG(%):
2.40		PREV:
3.750		LOW:
3.640		BID:
3.370		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
12 Jun 263.7503.8053.6403.6603.84M
11 Jun 263.6203.7903.5503.7504.07M
10 Jun 263.5003.7403.4803.6304.48M
09 Jun 263.4403.6003.4103.5704.91M
08 Jun 263.4503.5203.3753.3902.35M
05 Jun 263.5303.5303.3903.4003.25M
04 Jun 263.3503.5303.3403.5203.52M
03 Jun 263.4303.5253.3003.3603.49M
02 Jun 263.4903.5853.4103.4307.03M
01 Jun 263.7603.8103.4133.5308.35M

PROFILE

Name:Mannkind Corp
About:MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Sector:Healthcare
Industry:Biotechnology
Address:1 Casper Street, Danbury, CT, United States, 06810
Website:https://www.mannkindcorp.com
CUSIP:56400P201
CIK:0000899460
ISIN:US56400P7069
FIGI:BBG000PPL3G9
LEI:213800GFBCNY1ZFST722

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:127.40 
Forward P/E:11.20 
PEG Ratio:-0.50 
Price to Sales:5.57 
Price to Book:-15.35 
Profit Margin:0.11 
Operating Margin:0.14 
Return on Assets:0.11 
Return on Equity:-0.35 
EPS Ratio:0.02 
Revenue:301.74M 
EBITDA:93.13M 
Shares:308.1M 
Market Cap:1.128B 

TECHNICAL INDICATORS

MA5:3.601.7%
MA10:3.523.9%
MA20:3.446.5%
MA50:3.1018.2%
MA100:3.621.2%
MA200:4.5524.4%
STO9:67.42
STO14:51.72
RSI14:59.09
WPR14:-26.83
MTM14:0.13
ROC14:0.04 
ATR:0.22 
Week High:3.814.0%
Week Low:3.388.4%
Month High:3.947.7%
Month Low:2.9324.4%
Year High:6.5177.9%
Year Low:2.2364.1%
Volatility:14.31 

RECENT SPLITS

Date Ratio
03 Mar 20171-5